Results 1 to 10 of about 32,704 (143)
Global molecular diversity of RSV – the “INFORM RSV” study [PDF]
BMC Infectious Diseases, 2020 Background Respiratory syncytial virus (RSV) is a global cause of severe respiratory morbidity and mortality in infants. While preventive and therapeutic interventions are being developed, including antivirals, vaccines and monoclonal antibodies, little ...
A. Langedijk +28 more
semanticscholar +7 more sources
Immunopathology of RSV: An Updated Review [PDF]
Viruses, 2021 RSV is a leading cause of respiratory tract disease in infants and the elderly. RSV has limited therapeutic interventions and no FDA-approved vaccine. Gaps in our understanding of virus–host interactions and immunity contribute to the lack of biological ...
H. C. Bergeron, R. Tripp
semanticscholar +4 more sources
Socioeconomic Impact of RSV Hospitalization [PDF]
Infectious Diseases and Therapy, 2021 Respiratory syncytial virus (RSV) disease is a significant cause of morbidity and socioeconomic burden worldwide among young children. The majority of RSV-associated lower respiratory tract infections (LRTI) and mortality occurs in developing countries ...
M. Young, L. Smitherman
semanticscholar +4 more sources
The Journal of Infectious Diseases, 2022 BACKGROUND This United States-based study compared two candidate vaccines: RSV/ΔNS2/Δ1313/I1314L, attenuated by NS2 gene-deletion and temperature-sensitivity mutation in the polymerase gene; and RSV/276, attenuated by M2-2 deletion.
C. Cunningham +22 more
semanticscholar +3 more sources
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.
New England Journal of Medicine, 2023 BACKGROUND Whether vaccination during pregnancy could reduce the burden of respiratory syncytial virus (RSV)-associated lower respiratory tract illness in newborns and infants is uncertain.
B. Kampmann +40 more
semanticscholar +1 more source
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults.
New England Journal of Medicine, 2023 BACKGROUND Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F glycoprotein, is under clinical investigation.
Eleanor Wilson +32 more
semanticscholar +1 more source
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
New England Journal of Medicine, 2023 BACKGROUND The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab on hospitalizations for respiratory syncytial virus (RSV)-associated lower respiratory tract infection when administered in healthy infants are unclear. METHODS In
S. Drysdale +19 more
semanticscholar +1 more source
, 2021 Respiratory syncytial virus (RSV) hospitalizations disappeared in 2020. Now, with southern hemisphere 2021 winter behind us, RSV has returned. Despite it is difficult to weigh the impact of pandemic mitigation measures on common respiratory virus circulation, it appears that acute respiratory infections in children are returning to their usual ...
Fernando Ferrero +2 more
openaire +1 more source
An outbreak of RSV infections in a neonatology clinic during the RSV-season [PDF]
BMC Pediatrics, 2021 Abstract Background Respiratory syncytial virus (RSV) is the predominant cause of lower respiratory tract infections (LRTI) in infancy. Preterm infants with bronchopulmonary dysplasia (BPD) are at the highest risk of severe RSV-LRTI.
Liliya Vakrilova +4 more
openaire +3 more sources
Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.
New England Journal of Medicine, 2023 BACKGROUND Respiratory syncytial virus (RSV) can cause serious lower respiratory tract disease in older adults, but no licensed RSV vaccine currently exists.
A. Falsey +14 more
semanticscholar +1 more source